Scott D F, Moffett A
Department of Clinical Neurophysiology, London Hospital, England.
Acta Neurol Scand. 1988 Jun;77(6):498-502. doi: 10.1111/j.1600-0404.1988.tb05947.x.
Thirty drug-resistant epilepsy patients were given 20-30 mg of clobazam in addition to their other anticonvulsants and followed up for 2-3 years in an open-ended study. Fit frequency was markedly reduced in 43% of patients, few side effects occurred and psychological parameters including the Crown-Crisp questionnaire, showed improvement. It therefore seems that clobazam is a useful additional drug added to conventional anticonvulsant regimes.